CH457404A - Process for the production of new acetylene derivatives - Google Patents
Process for the production of new acetylene derivativesInfo
- Publication number
- CH457404A CH457404A CH1352565A CH1352565A CH457404A CH 457404 A CH457404 A CH 457404A CH 1352565 A CH1352565 A CH 1352565A CH 1352565 A CH1352565 A CH 1352565A CH 457404 A CH457404 A CH 457404A
- Authority
- CH
- Switzerland
- Prior art keywords
- aminomethyl
- chloroform
- solution
- indane
- compound
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 7
- 150000000475 acetylene derivatives Chemical class 0.000 title claims description 4
- 238000004519 manufacturing process Methods 0.000 title description 3
- -1 N-methyl-aminomethyl compound Chemical class 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 150000007522 mineralic acids Chemical class 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 claims description 3
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 125000003186 propargylic group Chemical group 0.000 claims 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 40
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 22
- 229960001701 chloroform Drugs 0.000 description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000012280 lithium aluminium hydride Substances 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 238000009835 boiling Methods 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000002026 chloroform extract Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- OPTNWMFSPWXSQD-UHFFFAOYSA-N 1-(2,3-dihydro-1h-inden-5-yl)-n-methylmethanamine Chemical compound CNCC1=CC=C2CCCC2=C1 OPTNWMFSPWXSQD-UHFFFAOYSA-N 0.000 description 3
- JJVNSSFYOJOECV-UHFFFAOYSA-N 2,3-dihydro-1h-inden-5-ylmethanamine Chemical compound NCC1=CC=C2CCCC2=C1 JJVNSSFYOJOECV-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- NBPDUBHQRMCPSY-UHFFFAOYSA-N 1-benzofuran-6-ylmethanamine Chemical compound NCC1=CC=C2C=COC2=C1 NBPDUBHQRMCPSY-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- UORVCLMRJXCDCP-UHFFFAOYSA-N propynoic acid Chemical compound OC(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-N 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- HFZZTHJMXZSGFP-UHFFFAOYSA-N 1-benzofuran-2-amine Chemical compound C1=CC=C2OC(N)=CC2=C1 HFZZTHJMXZSGFP-UHFFFAOYSA-N 0.000 description 1
- ZQGAXHXHVKVERC-UHFFFAOYSA-N 1-benzofuran-2-carbonitrile Chemical compound C1=CC=C2OC(C#N)=CC2=C1 ZQGAXHXHVKVERC-UHFFFAOYSA-N 0.000 description 1
- ARNCZJZLEMLOBH-UHFFFAOYSA-N 1-benzofuran-6-amine Chemical compound NC1=CC=C2C=COC2=C1 ARNCZJZLEMLOBH-UHFFFAOYSA-N 0.000 description 1
- KHEAFXLBELPDBH-UHFFFAOYSA-N 2,3-dihydro-1h-inden-4-ylmethanamine Chemical compound NCC1=CC=CC2=C1CCC2 KHEAFXLBELPDBH-UHFFFAOYSA-N 0.000 description 1
- VAZZQRFSDNZKPO-UHFFFAOYSA-N 2,3-dihydro-1h-indene-4-carbaldehyde Chemical compound O=CC1=CC=CC2=C1CCC2 VAZZQRFSDNZKPO-UHFFFAOYSA-N 0.000 description 1
- YNGGRNROMJXLCP-UHFFFAOYSA-N 2,3-dihydro-1h-indene-5-carbaldehyde Chemical compound O=CC1=CC=C2CCCC2=C1 YNGGRNROMJXLCP-UHFFFAOYSA-N 0.000 description 1
- FWWOWPGPERBCNJ-UHFFFAOYSA-N 2-hydroxy-4-(2-hydroxyethoxy)-4-oxobutanoic acid Chemical compound OCCOC(=O)CC(O)C(O)=O FWWOWPGPERBCNJ-UHFFFAOYSA-N 0.000 description 1
- RSZMTXPFGDUHSE-UHFFFAOYSA-N 2-nitro-1-benzofuran Chemical compound C1=CC=C2OC([N+](=O)[O-])=CC2=C1 RSZMTXPFGDUHSE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- JNXXDFFMOYDBCF-UHFFFAOYSA-N CN(CC#C)CC1=C2CCCC2=CC=C1 Chemical compound CN(CC#C)CC1=C2CCCC2=CC=C1 JNXXDFFMOYDBCF-UHFFFAOYSA-N 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- FRWXYISEMCIRDP-UHFFFAOYSA-N N-(1-benzofuran-6-ylmethyl)-N-methylprop-2-yn-1-amine Chemical compound CN(CC#C)CC=1C=CC2=C(OC=C2)C=1 FRWXYISEMCIRDP-UHFFFAOYSA-N 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 238000000297 Sandmeyer reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical class Cl* 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 150000001907 coumarones Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- JEVCWSUVFOYBFI-UHFFFAOYSA-N cyanyl Chemical compound N#[C] JEVCWSUVFOYBFI-UHFFFAOYSA-N 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical group [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 150000003948 formamides Chemical class 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical compound NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 description 1
- 229960003602 guanethidine Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 150000002468 indanes Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940072033 potash Drugs 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 230000002315 pressor effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Description
Verfahren zur Herstellung neuer Acetylen-Derivate D.'le vorliegende Erfindung betrifft ein Verfahren zur Herstellung neuer Acetylen-Derivate der Formel I,
EMI0001.0010
worin, A die Trimethylen'kette oder den Rest -CH=CH-O- bedeutet, und ihrer Säuread@ditionssalze.
Das erfindungsgemässe Verfahren ist dadurch ge kennzeichnet, dass man eine Verbindung der Formel II
EMI0001.0017
a) monomethyliert und die erhaltene N-Methyl-ami#no- meehyl-ver'bindung mit einem Propargyliha!1!ogenid umsetzt oder b) mit einem Propargylhad,ogenid umsetzt, das entstan dene Gemisch vom N-Monopropargy'1- und N,N-Di- propa#rgyl-aminomethyl-verb'mdu:
ugen auftrennt und die Monopropargyl-verbinidung monomet'hyliert und das Endprodukt gewünschtenfalls durch Umsetzung mit einer anorganischen oder organischen Säure in das entsprechende Salz überführt.
Als Verbindungen der Formel 1I verwendet man z. B. 6 - Aminomethylbenzo[b]furan., 4 - Am'uvomethyl- indan, 5-Aminomethyllindan usw.
Das Verfahren wird beispielsweise so ausgeführt, dass man die Amiuzomethylverbi:ndung II mit Chloramei- sensäureäthyl:ester in einer Mischung von rvässrigem Al- kali und einem mit Wasser nicht mischbaren organischen Lösungsmittel, wie Chloroform, umsetzt und- das erhal tene Urethan in einem inerten Lösungsmittel,
wie abs. Äther, Tetrahydrofuran oder Dioxan, mittels Lithium- ad,uminiumhydrid zur N-Methyl.amino-verbi!ndung redu- ziert.
Die Methylierung gelingt auch. durch Formyliierung der Verbindung 1I mit Ameisensäure und Reduktion 6-es entstandenen Formamid@s mittels Lit'hium- aluminiurnhydrid. Die N-Methylamin:
overbindung geht beim Erwärmen mit Propargylbromi@d in einem inerten Lösungsmittel, vorzugsweise Methylenchlorid, und in Gegenwart eines säurebindenden Mittels, z. B. eines Trialkyl.amins oder Pottasche, iin die gewünschte N-Me- thy'1 N-propargyl-ami!nome#thyl-verbindun:g über.
Man kann aber auch umgekehrt verfahren, indem man die Aminomet'hyl-verbindung 1I zuerst mit dem Propargylhalogenid behandelt, wodurch ein Gemisch von am Stickstoffatom mono- und' disubstituierten Deri vaten entsteht. Das Gemisch wird durch Destillation, Adsorptionschromatographie oder fraktionierte Kristalli sation eines geeigneten Salzes in die Komponente auf getrennt; die N-Monopropargyl-aminomethyl-verbindung wird hierauf methyliert, z.
B. durch Umsetzung mit Me- thyljo:did, Methylbromid usw., in Gegenwart eines säure bindenden MittdI's.
Verbindungen der Formel I sind in der Literatur bis her nicht beschrieben worden. Sie stellen bei Raumtem peratur ölige, farblose bis hellgelbe Basen dar, die in Wasser wenig, in den meisten organischen Lösungs mitteln dagegen leicht ,lösl'ic'h sind. Mit anorganischen und organischen Säuren bilden sie beständige, meist schön kristallisierte Salze, z. B.
Hydrochloride, Hyd'ro- bromid'e, Sulfate oder Methansulfonate, Äthan@sudfonate, p-Toluo#lsulfonate, Succinate, Hydrogenmaleinate, Fu- marate, Malate, Tartrate, Benzoate, Hexahydrobenzoate und so weiter.
Die neuen Verbindungen entfalten am hypertonen Versuchstier (Gro'llmann-Ratte) eine blutd'ruekse:nkend'e Wirkung. Sie unterdrücken die durch Guanethidin [N-(2- Gua@nid'inoäthyl)-octähydro-l-azocin] erzeugte initiale pressorische Wirkung (sympat'homimetischer Effekt), dass 'heisst sie hemmen die Freisetzung sympath'isc'her Über trägerstoffe (z.
B. Noradrenalin). Ferner besitzen sie eine starke Hemmwirkung auf die Monoaminoxydase in vivo und in vitro und sind Antagonisten zentraler, ins- besondere der krampffördernden und depressiven Effekte des Reserpins. Im Vergleich zu ihrer Wirksamkeit wei sen sie eine geringe Toxizität auf.
Die neuen Verbindungen können deshalb zur The rapie der Hypertonie und pectangi!nöser Zustände ver wendet werden, ;eignen sich aber auch zur medikamentö- sen Behandlung psychischer Erkrankungen, vor allem des depressiven Formenkreises. Als Heilmittel können sie - vorzugsweise in Form ihrer wasserlöslichen,
phy siologisch verträglichen Säureadditionssalze - allein oder in entsprechenden Arzneiformen für enterale oder par- enterale Verabreichung verwendet werden.
Die als Ausgangsprodukte verwendeten Amino- methylverbi'ndungen der Formel II können, je nach der Bedeutung von A, folgendermassen hergestellt werden: 1. Benzofuran-Derivate (A = -CH=CH-O-): Man geht von einem Nitrobenzo[b]furan aus, wel ches man durch.
Hydrierung in Gegenwart von: Raney- Nickel zur entsprechenden Aminoverbindwng reduziert; das 5- und das 6-Aminobenzo[b]furan sind übrigens schon beschrieben worden.
Das erhaltene Aminobenzo- [b]furan wird unter den Bedingungen der Sandmeyer- Reaktion, das heisst durch Diazotitrung und Austausch der Diazoniumgruppe gegen den Cyanrest mittels Kup- fer-I-cyanid, in das entsprechende Cyanbenzo[b]furan übergeführt.
Letzteres wird in einem iinerten Lösungs- mittel, z. B. Dioxan oder Tetrahyd@rofuran, mittels Li- thiumaluminium'hydrid, zur entsprechenden Amino- methylberbindung reduziert.
2. Indan-Derivate (A = Trimethylenkette): Man führt die bereits bekannten Farmyl-indane mit tels Hydroxylamin in ihre Oxime über und reduziert diese beispielsweise mittels Lithiumaluminiumhydrid in abs. Äther, Dioxan oder Tetrahydrofuran.
In den nachfolgenden Beispielen erfolgen alle Tem peraturangaben in Celsiusgraden; die Schmelzpunkte sind korrigiert. <I>Beispiel 1</I> 6-(N-Me'thyl-N-propargyl-aminomethyl)
- benzo[b]furan 10 g 6-Aminomethyl!benzo[b]fwran werden in 300 ml Chloroform gelöst und die Lösung mit 140 m4 Wasser überschichtet. Unter kräftigem Rühren werden bei einer Temperatur von 0-5 11.5 mil Chlo!rameisensäwreäthyl- ester und dann eine Lösung von 4,
7g Natrumhydroxyd in 100 m!1 Wasser zugetropft. Es wird 45 Min. bei Raumtemperatur gerührt, die Chlöroformphase abge- trennt, die wässrige Phase 2mal mit Chlorofo rm aus- geschüttelt,
die vereinigten Chloroformexltrakte 4mal' mit 2n Salzsäure ausgeschüttelt, über Magnesiumsulfat ge trocknet und eingedampft. Das als hellgelbes Öl erhaf- tene 6 - (N-Äthoxycarbounyl-aminomethyl)
-benzo[b]furan wird in 50 ml Tetrahydrofvran gelöst und diese Lösung bei einer Temperatur von 80 langsam in eine Suspen sion von 8,9 g Lithiumalumiriiumhydrid in 90 mil. Tetra- hydrofuran eingetropft. Die Mischung wird, 45 Min. am Rückfluss zum Sieden erhitzt,
überschüssiges Lithium- aluminiumhydrid mit Methanol zersetzt und das Ganze nach Versetzen mit ges. Natriumsulfatlösung mit ChAoro- form ausgeschüttelt. Nach Trocknen über Magnesium- sulfa't und Abdest'! i fieren des Chloroforms erhält man
das 6-(N-Methyl-amihomethyl)-benzo[b]furan lhell- gelbes Ö<B>l</B>. Das Bimaleinat kristallisiert aus Essigester ih langen, farblosen Nad'el'n vom Smp. 122-123 .
Zu einer Lösung von 4,5 g 6-(N-Methyl!-amno- methyl)=benzo[b]furan in 50 ml Methylenchlord werden 5 mil Trimethyfamin gegeben und dann 3,65 g Propargy'1- bromid zugetropft; dabei steigt die Temperatur auf 35 bis 40 .
Nach beendetem Zutropfen wird 2 Std. am Rückfluss zum Sieden erhitzt, dann abgekühlt und mit 100 xnf Wasser versetzt. Nach Zugabe von 100 ml 10 % iger Weinsäuzelösung wird durchgeschüttelt, die weinsaure Phase abgetrennt, über hochgereinigte FwlIer- erde filtn:
ert und unter Kühlung mit 2n Nafironliauge al- kaisch gestellt. Die alkalische Lösung wird mit Chloro form ausgeschüttelt, die Chl'oroformextrakte über Ma- gnes umsulfat getrocknet und eingeengt.
Der Rückstand -Wird an Kieselgeil mit Chloroform/Essigester chromato- grap'hiert. Man erhält das 6-(N-Methyl-N-propaurgyl- amiro:omethyd)=benzo[b]furan als helilgelbes Ö'1. Sein Hydrochlorid, kristallisiert aus Äthanal/Äther in Form feiner Nädellchen vom Sm#p. 197-198 .
Das Ausgangsprodukt kann beispielsweise folgen- dermassen hergestellt werden: 6-Amino-b:
enzo[b]furan wird in halbkonzentrierter Salzsäure suspendiert RTI ID="0002.0240" WI="6" HE="4" LX="1456" LY="1006"> und mit der ent'sprechend'en Menge Natriumuührit (gelöst in Wasser)
bei 0-5 diazotiert. Die nahezu neutralisierte Diazoniumsalzlösung lässt man bei derselben Temperatur in eine wässrige Lösung von Kup- fer-I-dhdorid und Natriumcyanid einitropfen. Nach kur zem Erhitzen wird die Mischung mit Äther extrahiert, die organische Phase abgetrennt und eingedampft und der Rückstand chromato.graphisch gereinigt.
Man er hält 6-Cya@no-benzo[b]fwran als 'tiefrotes Öl vom Sdp. 73 bis 75 /0,01 mm Hg.
Durch Reduktion des 6-Cyan.o-benzo[b]fura@us mit Lith#i,uma,llumin#iumhydrid in abs. Tetrahyd!rofuran erhält man 6-Aminomethyl-benzo[b]furan. in Form farbloser Nadeln vom Smp.95-98 (nach Kristallisation aus Ligromn). Smp. des Bitartrats 191-l93 (massive Pris men aus Methanol/Äther).
<I>Beispiel 2</I> 5-(N-Methyll\N-p\ro'pargyl'-aminomethyl)-indan Eine Lösung von 3,05 g 5-Aminomethyl'-indan in 80 m1 Chloroform wird mit 38 ml Wasser überschichet. Unter kräftigem Rühren werden bei einer Temperatur von 0-5 3,75 m1 Chlorameisensäure-äthylester und dann eigne Lösung von 1,
55 g Natriümhydroxyd in 33 ml Wasser zugetropft. Man rührt 30 Min. bei Raum temperatur, trennt die Chloroformphase ab und schüt telt die wässrige Phase 2mal mit Chloroform aus;
d!ie vereinigten Chloroformejetrakte werden 4mal mit 2n Salzsäure ausgeschüttelit, über Magnesiumsulfat getrock net und eihgedampft. Das erhaltene 5-(N-Äth.oxycarbo- nyl-aminomethyl)-indan (Smp.59-60 , Nadeln aus Pefiroläther)
wird in 65 ml Tetrahydrofuran gelöst und diese Lösung bei einer Temperatur von 70 langsam in einte Suspension von 3,7 g Lithiumaluminiumhydrid in 65 m'1 Tetrahydrofuran eingetropft. Die Mischung wird 1 Std.
am Rückfluss zum Sieden erhitzt, übersdhüssiges Lithhiumäuminiumhydrid mit Methanol zersetzt und das Ganze nach Versetzen mit gesättigter Natriumsulfat- lösung mit Chloroform ausgeschüttelt. Nach.
Trocknen über Magnesiumsulfat und Abdestiüieren des Chloro forms erhält man das 5-Methylaminomethyl-indan als hellgelbes Öl vom Sdp. 115-120 /12 mm Hg.
Zu einer Lösung von 2,9 g 5-Methylaminomethyl- indan in 5 ml Methylenchlorid wird eine Lösung von 1 g Propargy1bromid in 8 ml Meth:
ylenchlorid zuge- tropft, wobei die Temperatur auf 35-40 ansteigt. An schliessend erhitzt man 11/2 Std. am Rückfluss zum Se- den, kühlt ab und fällt das nicht umgesetzte 5-Methyl- aminomet'hyl-indan durch: Zugabe von Äther als Hydro- b@romid aus.
Man fätriert, dampft das Filtrat ein, chro- matograph:zert den Rückstand an Kieselgel mit Chloro form und erhält das 5-(N-Methyi-N propargyl-amino- methyl)-indan als hellgelbes Öl voran Sdp.100-105 / <B>0,01</B> mm Hg. Sein Bimafelnat kristallisiert aus.
Metha- nol/Essigester ein Prismen vom Smp. 112-113'.
Das als Ausgangsmaterial benötigte 5-Amimomet'hyl- indan erhält man wie folgt: Ind'a)n-5-alde'hyd wird mit Hydroxylamin-hydrochlo- rid zum Indan-5-al'dehyd-oxim (Sdp. 110-115 /0,01 mm Hg) umgesetzt, das man anschliessend mit Li'thiurn- aluminium!hydrid zu 5-Aminomethyl-indan reduziert. Sdp. 100-105 /0,01 mm Hg.
<I>Beispiel 3</I> 4-(N-Methyl-N-2-propinyl-aminomethyl)-indan Eine Lösung von 3,7 g 4-Aminomethyl-indan in 100 ml Chloroform wird mit 45 m'1 Wasser überschich- tet. Unter kräftigem Rühren werden bei einer Tempe ratur von 0-5 4,6 m'1 Chil.orameisensäureäthyles:
ter und dann eine Lösung von 1,9 g Naroriumhydroxy'in 40 m1' Wasser zugetropft. Man rührt 30 Min. bei Raumtempe ratur, trennt die Ch 'oroformphase ab und schüttelt die wässrige Phase 2mal mit Chloroform aus;
die vereinigten Chlo@roformextrakte werden 4mal mit 2n Salzsäure aus- geschüttelt, über Magnesium:sulfat getrocknet und ein gedampft.
Das erhaltene 4-(N-Äthoxycarbonyl-amino- methyl)-ind'an wird in 80 ml' Tetrahydrofuran gelöst und diese Lösung bei einer Temperatur von 70 langsam in eine Suspension von 4,55g Lit'hiumaluminiumhydrid in 80 ml Tetrahydrofuran eingetropft. Die Mischung wird 1 Std.
am Rückfluss zum Sieden erhitzt, überschüssiges Lithiumailuminiunihydrid mit Methanol zersetzt und das Ganze nach Versetzen mit gesättigter Natriumsulfa't- lösung mit Chloroform ausgeschüttelt. Nach Trocknen über Magnesiumsulfat und Abdestillieren dies Chloro forms erhält man das
4-Methy lanmiinomethyl-indan als hellgelbes<B>Öl</B> vom Sdp. 113-120 /11 mm Hg (Tempera tur im Luftbad gemessen).
Zu einer Lösung von 4,25 g 4-Methylamnoineihhyl- i,nda'n in 7,5 m'1 Methylenchlorid wird eine Lösung von 1,47 g Propargylbromid in 12 mal Methyl',enchforid zu getropft, wobei die Temperatur auf etwa 40 ansteigt.
Anschliessend erhitzt man l1/2 Std. am Rückfluss zum Sieden, kühlt ab und fällt das nichtumgesetzte 4-Me- thylaminome,thyl-indan durch Zugabe von Äther als Hydro'bromid aus.
Man filtriert, dampft das Filtrat ein, chromato,grap'hiert den Rückstand an Kieselgel mit Chloroform und erhält das 4-(N-Met'hyl-N-pro;pargyl- aminomethyl)-inda#n als hellgelbes Öl vom Sd'p. 98 bis 106 /0,01 mm Hg (Temperatur im Luftbad gemessen). Sein Methansulfonat kristallisieret aus Essigester in Pris men vom Smp. 163-165 .
Das als Ausgangsmaterial benötigte 4-Ami(nometh@yl- ind'an erhält man wie folgt: Indan-4-al'dehyd wird mit I-lydr.oxylamin-'hjydrochlo- ri,d zum Indan - 4 - aIdehy d-oxim (Sdp. 120-125 / 0,1 mm Hg) umgesetzt,
das man anschliessend mit Li- 'thiumaluminiumhydrid zum 4-Amimomethyl-indan re duziert. Sd!p. 103-105 /0,05 mm Hg.
<I>Beispiel 4</I> 5-(N-Mothyl-N-propargy'1-aminomethy'1)-indan Zu einer Lösung von 16,2 g 5-Amiinomelt'hyl ndan in 50 ml Methylenchlorid wird eine Lösung von 6,45 g Propargylbromid in 25 ml Methylenchlorid zugetropft. Main, lässt 4 Std.
bei Raumtemperatur rühren, fällt dann durch Zugabe von Äther das nicht umgesetzte 5-Amino- methyl-indan als Hydrobromid aus, filtriert: und dampft das Filtrat ein.
Durch Chromatographie des Rückstan des an Kieselgel mit Chloroform erhält man das 5-(N- Propargyl-aminomethyl)-in@dan als gelbliches Öl vom Siedepunkt 105-110 /0,1 mm Hg.
20 g 5-(N-Propargyl-anminomet'hyl)-indan werden in 50 ml Methylenchlorid gelöst und unter Rühren und Eiskühlung 'tropfenweise mit einer Lösung von 7,1 g Methyljodid in 50 ml Methylenchl'orid versetzt.
Man rührt anschliessend 5 Std. bei Raumtemperatur, fällt dann d'urc'h Zugabe von Äther das nicht urangesetzte 5-(N-Propargyd-ami@nomethyl)-indan als Hydrojodid aus und filtriert. Das Filtrat wird eingedampft und der ölige Rückstand an Kieselgel mit Chloroform chromatogra- p!hiert. Man erhält das 5-(N-Me,t'hyl-N-propargyl-amino- methyl)-in,
dan als hellgelbes <B>Öl</B> vom Siedepunkt 100 bis 105 /0,01 mm Hg. Sein Bim@alleinat kristallisiert aus Met'han:ol/Essigester in Prismen vom Smp. 112-113 .
Process for the production of new acetylene derivatives D.'le present invention relates to a process for the production of new acetylene derivatives of the formula I,
EMI0001.0010
in which, A denotes the trimethylene chain or the radical -CH = CH-O-, and its acid addition salts.
The inventive method is characterized in that a compound of the formula II
EMI0001.0017
a) monomethylated and the N-methyl-aminomethyl compound obtained is reacted with a propargylic acid or b) reacted with a propargylic acid, the resulting mixture of N-monopropargyl and N , N-di- propa # rgyl-aminomethyl-verb'mdu:
ugen separates and the monopropargyl compound monomethylated and the end product, if desired, converted into the corresponding salt by reaction with an inorganic or organic acid.
Compounds of formula 1I are used, for. B. 6 - aminomethylbenzo [b] furan., 4 - am'uvomethylindane, 5-aminomethylindane etc.
The process is carried out, for example, by reacting the amiuzomethylverbi: ndung II with ethyl chloroformate in a mixture of aqueous alkali and a water-immiscible organic solvent, such as chloroform, and the urethane obtained in an inert one Solvent,
like abs. Ether, tetrahydrofuran or dioxane, reduced to the N-methylamino compound by means of lithium ad, ammonium hydride.
The methylation also succeeds. Formamides formed by formylation of the compound 1I with formic acid and reduction 6-es by means of lithium aluminum hydride. The N-methylamine:
Overbinding goes on heating with Propargylbromi @ d in an inert solvent, preferably methylene chloride, and in the presence of an acid-binding agent, for. B. a trialkyl amine or potash, into the desired N-methy'1 N-propargyl-aminomethyl compound.
However, the reverse procedure can also be used by first treating the aminomethyl compound 1I with the propargyl halide, which results in a mixture of derivatives which are mono- and disubstituted on the nitrogen atom. The mixture is separated into the component by distillation, adsorption chromatography or fractional crystallization of a suitable salt; the N-monopropargyl aminomethyl compound is then methylated, e.g.
B. by reaction with methyljo: did, methyl bromide, etc., in the presence of an acid-binding agent.
Compounds of the formula I have not yet been described in the literature. At room temperature, they are oily, colorless to pale yellow bases which are slightly soluble in water and slightly soluble in most organic solvents. With inorganic and organic acids they form stable, mostly nicely crystallized salts, e.g. B.
Hydrochloride, hydrobromide, sulfate or methane sulfonate, ethane @ sudfonate, p-toluene sulfonate, succinate, hydrogen maleate, fumarate, malate, tartrate, benzoate, hexahydrobenzoate and so on.
The new compounds develop a blood pressure on the hypertonic test animal (Gro'llmann rat). They suppress the initial pressor effect (sympathetic homimetic effect) produced by guanethidine [N- (2- Gua @ nid'inoethyl) -octahydro-l-azocine], which means that they inhibit the release of sympathetic carrier substances ( z.
B. norepinephrine). Furthermore, they have a strong inhibitory effect on monoamine oxidase in vivo and in vitro and are more central antagonists, in particular of the convulsive and depressive effects of reserpine. Compared to their effectiveness, they show low toxicity.
The new compounds can therefore be used for the therapy of hypertension and pectangiose conditions, but are also suitable for the drug treatment of mental illnesses, especially the depressive type. They can be used as remedies - preferably in the form of their water-soluble,
physiologically acceptable acid addition salts - can be used alone or in appropriate dosage forms for enteral or parenteral administration.
The amino methyl compounds of the formula II used as starting materials can, depending on the meaning of A, be prepared as follows: 1. Benzofuran derivatives (A = -CH = CH-O-): One starts from a nitrobenzo [b] furan from which one to go through.
Hydrogenation in the presence of: Raney nickel reduced to the corresponding amino compound; the 5- and 6-aminobenzo [b] furan have already been described.
The aminobenzo- [b] furan obtained is converted into the corresponding cyanobenzo [b] furan under the conditions of the Sandmeyer reaction, ie by diazotitration and replacement of the diazonium group for the cyano radical by means of copper-I-cyanide.
The latter is in an inert solvent, e.g. B. dioxane or Tetrahyd @ rofuran, by means of lithium aluminum hydride, reduced to the corresponding aminomethyl bond.
2. Indane derivatives (A = trimethylene chain): The already known farmyl-indanes are converted into their oximes using hydroxylamine and these are reduced, for example, using lithium aluminum hydride in abs. Ether, dioxane or tetrahydrofuran.
In the following examples, all temperatures are given in degrees Celsius; the melting points are corrected. <I> Example 1 </I> 6- (N-methyl-N-propargyl-aminomethyl)
- benzo [b] furan 10 g of 6-aminomethyl! benzo [b] furan are dissolved in 300 ml of chloroform and the solution is covered with 140 m4 of water. While stirring vigorously at a temperature of 0-5, 11.5 mil chloroformic acid ethyl ester and then a solution of 4,
7g sodium hydroxide in 100 ml water was added dropwise. The mixture is stirred for 45 minutes at room temperature, the chloroform phase is separated off, the aqueous phase is shaken out twice with chloroform,
the combined chloroform extracts extracted 4 times' with 2N hydrochloric acid, dried over magnesium sulfate and evaporated. The 6 - (N-ethoxycarbounyl-aminomethyl) obtained as a light yellow oil
Benzo [b] furan is dissolved in 50 ml of tetrahydrofuran and this solution is slowly added dropwise at a temperature of 80 to a suspension of 8.9 g of lithium aluminum hydride in 90 mil. tetrahydrofuran. The mixture is refluxed for 45 min.
Excess lithium aluminum hydride decomposed with methanol and the whole thing after adding sat. Shake out sodium sulfate solution with ChAoroform. After drying over magnesium sulfate and distillation! i fiering the chloroform is obtained
the 6- (N-methyl-amihomethyl) -benzo [b] furan lpight yellow Ö <B> l </B>. The bimaleate crystallizes from ethyl acetate in long, colorless needles of melting point 122-123.
To a solution of 4.5 g of 6- (N-methyl! -Amnomethyl) = benzo [b] furan in 50 ml of methylene chloride are added 5 mil of trimethylamine and then 3.65 g of propargy-1-bromide are added dropwise; the temperature rises to 35 to 40.
When the dropwise addition is complete, the mixture is heated to boiling under reflux for 2 hours, then cooled and mixed with 100 × nf water. After adding 100 ml of 10% tartaric acid solution, it is shaken, the tartaric acid phase is separated off, filtered over highly purified soil:
and placed in alkaline condition with cooling with 2N Nafirone lye. The alkaline solution is shaken out with chloroform, the chloroform extracts are dried over magnesium sulfate and concentrated.
The residue is chromatographed on silica gel with chloroform / ethyl acetate. The 6- (N-methyl-N-propaurgyl-amiro: omethyd) = benzo [b] furan is obtained as a pale yellow oil. Its hydrochloride, crystallized from ethanal / ether in the form of fine needles from Sm # p. 197-198.
The starting product can be produced, for example, as follows: 6-Amino-b:
enzo [b] furan is suspended in half-concentrated hydrochloric acid RTI ID = "0002.0240" WI = "6" HE = "4" LX = "1456" LY = "1006"> and with the corresponding amount of sodium hydroxide (dissolved in Water)
diazotized at 0-5. The almost neutralized diazonium salt solution is allowed to drip into an aqueous solution of copper-I-dhoride and sodium cyanide at the same temperature. After brief heating, the mixture is extracted with ether, the organic phase is separated off and evaporated and the residue is purified by chromatography.
6-Cya @ no-benzo [b] fwran is obtained as a deep red oil with a boiling point of 73 to 75 / 0.01 mm Hg.
By reducing the 6-cyano-benzo [b] fura @ us with lith # i, uma, llumin # iumhydrid in abs. Tetrahydrofuran gives 6-aminomethylbenzo [b] furan. in the form of colorless needles with a melting point of 95-98 (after crystallization from ligromine). M.p. des bitartrate 191-193 (massive prisms made of methanol / ether).
<I> Example 2 </I> 5- (N-methyll \ Np \ ro'pargyl'-aminomethyl) -indane A solution of 3.05 g of 5-aminomethyl'-indane in 80 ml of chloroform is covered with 38 ml of water . While stirring vigorously at a temperature of 0-5, 3.75 ml of ethyl chloroformate and then its own solution of 1,
55 g of sodium hydroxide in 33 ml of water were added dropwise. The mixture is stirred for 30 minutes at room temperature, the chloroform phase is separated off and the aqueous phase is extracted twice with chloroform;
the combined chloroform extracts are extracted 4 times with 2N hydrochloric acid, dried over magnesium sulfate and evaporated. The 5- (N-Äth.oxycarbonyl-aminomethyl) -indane obtained (m.p. 59-60, needles from pefirolether)
is dissolved in 65 ml of tetrahydrofuran and this solution is slowly added dropwise at a temperature of 70 to a suspension of 3.7 g of lithium aluminum hydride in 65 ml of tetrahydrofuran. The mixture is 1 hour.
Heated to boiling under reflux, excess lithium aluminum hydride is decomposed with methanol and the whole is shaken out with chloroform after addition of saturated sodium sulfate solution. To.
Drying over magnesium sulfate and distilling off the chloro form gives 5-methylaminomethyl-indane as a pale yellow oil with a boiling point of 115-120 / 12 mm Hg.
To a solution of 2.9 g of 5-methylaminomethylindane in 5 ml of methylene chloride is a solution of 1 g of propargyl bromide in 8 ml of meth:
ylene chloride was added dropwise, the temperature rising to 35-40. The mixture is then refluxed for 11/2 hours, cooled, and the unconverted 5-methylaminomethylindane precipitates by adding ether as hydroboromide.
It is filtered, the filtrate is evaporated, chromatograph: the residue is broken up on silica gel with chloroform and the 5- (N-methyi-N propargyl-aminomethyl) -indane is obtained as a light yellow oil, bp.100-105 / < B> 0.01 </B> mm Hg. Its Bimafelnat crystallizes out.
Methanol / ethyl acetate is a prism with a melting point of 112-113 '.
The 5-amimomethyl-indane required as starting material is obtained as follows: Ind'a) n-5-alde'hyd is converted into indane-5-al'dehyde oxime with hydroxylamine hydrochloride (bp 110-115 / 0.01 mm Hg), which is then reduced to 5-aminomethylindane with lithium aluminum hydride. 100-105 / 0.01 mm Hg.
<I> Example 3 </I> 4- (N-Methyl-N-2-propynyl-aminomethyl) -indane A solution of 3.7 g of 4-aminomethyl-indane in 100 ml of chloroform is covered with 45 ml of water - tet. While stirring vigorously at a temperature of 0-5, 4.6 ml / 1 chilli oroformic acid ethyls:
ter and then a solution of 1.9 g of sodium hydroxide in 40 ml of water was added dropwise. The mixture is stirred for 30 minutes at room temperature, the chloroform phase is separated off and the aqueous phase is extracted twice with chloroform;
the combined chloroform extracts are shaken out 4 times with 2N hydrochloric acid, dried over magnesium sulfate and evaporated.
The 4- (N-ethoxycarbonyl-aminomethyl) -ind'an obtained is dissolved in 80 ml of tetrahydrofuran and this solution is slowly added dropwise at a temperature of 70 to a suspension of 4.55 g of lithium aluminum hydride in 80 ml of tetrahydrofuran. The mixture is 1 hour.
Heated to the boil under reflux, excess lithium aluminum hydride is decomposed with methanol and the whole thing is extracted with chloroform after adding saturated sodium sulfate solution. After drying over magnesium sulfate and distilling off this chloro forms, one obtains the
4-Methy lanminomethyl-indane as a light yellow <B> oil </B> with a bp. 113-120 / 11 mm Hg (temperature measured in an air bath).
A solution of 1.47 g of propargyl bromide in 12 times methylene chloride is added dropwise to a solution of 4.25 g of 4-methylamnoineihhyl- i, nda'n in 7.5 ml of methylene chloride, the temperature increasing to about 40% increases.
The mixture is then refluxed for 11/2 hours, cooled and the unconverted 4-methylaminome, thyl-indane is precipitated as hydrobromide by adding ether.
It is filtered, the filtrate is evaporated, chromatographed, the residue is graphed on silica gel with chloroform and the 4- (N-methyl-N-pro; pargyl-aminomethyl) -inda # n is obtained as a pale yellow oil from Sd'p . 98 to 106 / 0.01 mm Hg (temperature measured in an air bath). Its methanesulfonate crystallizes from ethyl acetate in prisms with a melting point of 163-165.
The 4-ami (nometh @ yl-ind'ane required as starting material is obtained as follows: indane-4-al'dehyde is converted into indane-4-aldehyde-oxime with 1-hydroxylamine-'hydrochloride, d (Bp. 120-125 / 0.1 mm Hg) implemented,
which is then reduced to 4-amimomethylindane with lithium aluminum hydride. Sd! P. 103-105 / 0.05 mm Hg.
<I> Example 4 </I> 5- (N-Mothyl-N-propargy'1-aminomethy'1) -indane To a solution of 16.2 g of 5-aminomethylndane in 50 ml of methylene chloride is added a solution of 6.45 g of propargyl bromide in 25 ml of methylene chloride were added dropwise. Main, leaves 4 hours
stir at room temperature, the unreacted 5-amino-methyl-indane then precipitates out as a hydrobromide by adding ether, filtered: and the filtrate is evaporated.
Chromatography of the residue on silica gel with chloroform gives 5- (N-propargyl-aminomethyl) -in @ dan as a yellowish oil with a boiling point of 105-110 / 0.1 mm Hg.
20 g of 5- (N-propargyl-anminomethyl) -indane are dissolved in 50 ml of methylene chloride and a solution of 7.1 g of methyl iodide in 50 ml of methylene chloride is added dropwise, while stirring and cooling with ice.
The mixture is then stirred for 5 hours at room temperature, then the non-urinary 5- (N-propargyd-aminomethyl) -indane precipitates out as hydroiodide and filtered. The filtrate is evaporated and the oily residue is chromatographed on silica gel with chloroform. The 5- (N-Me, t'hyl-N-propargyl-aminomethyl) -in is obtained,
then as a light yellow oil with a boiling point of 100 to 105 / 0.01 mm Hg. Its Bim @ alone crystallizes from Met'han: ol / ethyl acetate in prisms with a melting point of 112-113.
Claims (1)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1352565A CH457404A (en) | 1965-09-30 | 1965-09-30 | Process for the production of new acetylene derivatives |
| NL6613360A NL6613360A (en) | 1965-09-30 | 1966-09-22 | |
| FR77981A FR1494630A (en) | 1965-09-30 | 1966-09-28 | New acetylenic amines and their preparation |
| ES0331671A ES331671A1 (en) | 1965-09-30 | 1966-09-28 | PROCEDURE FOR THE PRODUCTION OF ACETYLENE DERIVATIVES. |
| BE687490D BE687490A (en) | 1965-09-30 | 1966-09-28 | |
| ES0331672A ES331672A1 (en) | 1965-09-30 | 1966-09-28 | Procedure for the production of acetylene derivatives. (Machine-translation by Google Translate, not legally binding) |
| AT912866A AT267498B (en) | 1965-09-30 | 1966-09-29 | Process for the preparation of new N-methyl-N-benzyl-propargylamines and their acid addition salts |
| AT912966A AT268240B (en) | 1965-09-30 | 1966-09-29 | Process for the preparation of new N-methyl-N-benzyl-propargylamines and their acid addition salts |
| FR88836A FR6071M (en) | 1965-09-30 | 1966-12-26 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1352565A CH457404A (en) | 1965-09-30 | 1965-09-30 | Process for the production of new acetylene derivatives |
| CH1352665 | 1965-09-30 | ||
| CH662866 | 1966-05-06 | ||
| CH686966 | 1966-05-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH457404A true CH457404A (en) | 1968-06-15 |
Family
ID=27429006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1352565A CH457404A (en) | 1965-09-30 | 1965-09-30 | Process for the production of new acetylene derivatives |
Country Status (6)
| Country | Link |
|---|---|
| AT (1) | AT267498B (en) |
| BE (1) | BE687490A (en) |
| CH (1) | CH457404A (en) |
| ES (1) | ES331671A1 (en) |
| FR (1) | FR6071M (en) |
| NL (1) | NL6613360A (en) |
-
1965
- 1965-09-30 CH CH1352565A patent/CH457404A/en unknown
-
1966
- 1966-09-22 NL NL6613360A patent/NL6613360A/xx unknown
- 1966-09-28 BE BE687490D patent/BE687490A/xx unknown
- 1966-09-28 ES ES0331671A patent/ES331671A1/en not_active Expired
- 1966-09-29 AT AT912866A patent/AT267498B/en active
- 1966-12-26 FR FR88836A patent/FR6071M/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| AT267498B (en) | 1968-12-27 |
| NL6613360A (en) | 1967-03-31 |
| BE687490A (en) | 1967-03-28 |
| FR6071M (en) | 1968-05-27 |
| ES331671A1 (en) | 1967-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2434911C2 (en) | Phenylethylamine derivatives and pharmaceutical compositions | |
| DE2752659A1 (en) | NEW TETRALINE DERIVATIVES, THEIR PRODUCTION AND USE | |
| DD156369A5 (en) | PREPARATION OF RIGHT-TURNING 5-ARYL-2,3,4,4A, 5,9B-HEXAHYDRO-1H-PYRIDO [4,3B] -INDOLENES | |
| DE2851028A1 (en) | NEW INDOLO SQUARE CLAMP ON 2.3-A SQUARE CLAMP ON CHINOLICIDINE, METHOD FOR THEIR PRODUCTION AND PHARMACEUTICAL PREPARATION CONTAINING IT | |
| DE2413102A1 (en) | PROCESS FOR THE PRODUCTION OF 1- (3,5DIHYDROXYPHENYL) -1-HYDROXY-2-SQUARE CLIP ON 1-METHYL-2- (4-HYDROXYPHENYL) -AETHYL SQUARE CLIP FOR -AMINO-ETHANE | |
| DE1568277B2 (en) | OPTICALLY ACTIVE PHENYLISOPROPYLAMINE DERIVATIVES, THEIR PRODUCTION AND PREPARATIONS CONTAINING THESE COMPOUNDS | |
| DE2737738C2 (en) | 3-Amino-thiophene-4-carboxylic acids and their derivatives, processes for their preparation and pharmaceutical compositions containing them | |
| EP0000395B1 (en) | 2-piperazinotetraline derivatives, their preparation and their use as medicines | |
| DE1518973A1 (en) | Process for the preparation of dibenzocycloheptatriene compounds | |
| DE2332707A1 (en) | TRICYCLIC TETRAHYDRONAPHTHALINE DERIVATIVES, THEIR SALTS, METHODS FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS | |
| CH457404A (en) | Process for the production of new acetylene derivatives | |
| DE2833892C2 (en) | 12H-dibenzo [d, g] [1,3,6] dioxazocine derivatives, medicaments containing them and processes for the preparation thereof | |
| AT202152B (en) | Process for the preparation of new dimethylaminopropylidene thiaxanthenes. | |
| CH610330A5 (en) | Process for the preparation of novel ergopeptins | |
| EP0056617A2 (en) | Cycloheptene derivatives, process and intermediates for their preparation, and pharmceuticals containing them | |
| EP0000013A1 (en) | 4-Phenyl-8-amino-tetrahydroisoquinolines, pharmaceutical compositions containing them and process for preparation of these compositions | |
| BE1000112A5 (en) | METHOD FOR PREPARING encainide. | |
| AT360992B (en) | METHOD FOR PRODUCING NEW PHENYLAZACYCLO-ALKANS AND THEIR SALTS AND OPTICALLY ACTIVE COMPOUNDS | |
| AT338793B (en) | PROCESS FOR PRODUCING NEW BENZAZOCINE DERIVATIVES | |
| AT233552B (en) | Process for the preparation of new dibenzocycloheptadiene derivatives and their salts | |
| DE1768615C3 (en) | Amides of 2-hydroxy-3-methoxy-5-allyl-benzoic acid, process for their preparation and medicaments containing them | |
| CH449647A (en) | Compounds for the preparation of substituted hydrazine compounds | |
| AT227690B (en) | Process for the production of new, basic substituted succinimides | |
| AT208867B (en) | Process for the preparation of new substituted heterocyclic acid hydrazides | |
| AT400146B (en) | Process for the preparation of 1-(2-((5-dimethylamino methyl-2-furyl)methylthio)ethyl)amino-1-methylamino-2- nitroethylene |